Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

OBJECTIVES: We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory squamous cell carcinoma of the head and neck (SCCHN). METHODS: Patient...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oral Oncol
Main Authors: Ferris, Robert L., Blumenschein, George, Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Harrington, Kevin J., Kasper, Stefan, Vokes, Everett E., Even, Caroline, Worden, Francis, Saba, Nabil F., Docampo, Lara Carmen Iglesias, Haddad, Robert, Rordorf, Tamara, Kiyota, Naomi, Tahara, Makoto, Lynch, Mark, Jayaprakash, Vijayvel, Li, Li, Gillison, Maura L.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563923/
https://ncbi.nlm.nih.gov/pubmed/29884413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2018.04.008
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares